nach oben

Investigational New Drugs

Erschienen in:

01.10.2011 | SHORT REPORT

Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan

verfasst von: Moon Jin Kim, Gyeong-Won Lee, Jong Woo Seo, Hyun-Jung Kim, Sung-Nam Lim, Cheolwon Suh

Erschienen in: Investigational New Drugs | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Summary

There is no previous report of fatal interstitial pneumonitis related to the administration of yttirum-90 ibritumomab tiuxetan. We report first case of fatal interstitial pneumonitis in a 35-year-old female patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan. A pathological evaluation through a surgical lung biopsy demonstrated a “interstitial pneumonitis” pattern. Although high-dose methylprednisolone was administered, she died due to acute respiratory distress syndrome, secondary to radioimmunotherapy-induced interstitial pneumonitis. In this report, we discuss the etiology, diagnosis, and management of radioimmunotherapy-induced interstitial pneumonitis.

Marcus R (2005) Use of 90Y-ibritumomab tiuxetan in non-Hodgkin’s lymphoma. Semin Oncol 32:S36–S43PubMedCrossRef

Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453–2463PubMedCrossRef

Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S et al (2003) Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials. J Nucl Med 44:465–474PubMed

Macklis RM, Pohlman B (2006) Radioimmunotherapy for non-Hodgkin’s lymphoma: a review for radiation oncologists. Int J Radiat Oncol Biol Phys 66:833–841PubMedCrossRef

Burton C, Kaczmarski R, Jan-Mohamed R (2003) Interstitial pneumonitis related to rituximab therapy. N Engl J Med 348:2690–2691PubMedCrossRef

Macartney C, Burke E, Elborn S, Magee N, Noone P, Gleadhill I et al (2005) Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin’s lymphoma following R-CHOP and pegylated filgrastim. Leuk Lymphoma 46:1523–1526PubMedCrossRef

Kim KM, Kim HC, Jeon KN, Kim HG, Kang JH, Hahm JR et al (2008) Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. Yonsei Med J 49:155–158PubMedCrossRef

Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P (2009) The late adverse events of rituximab therapy—rare but there! Leuk Lymphoma 50:1083–1095PubMedCrossRef

DeMonaco NA, McCarty KS Jr, Joyce J, Jacobs SA (2007) Focal radiation fibrosis after radioimmunotherapy for follicular non-Hodgkin lymphoma. Clin Lymphoma Myeloma 7:369–372PubMedCrossRef

10.

Salem R, Parikh P, Atassi B, Lewandowski RJ, Ryu RK, Sato KT et al (2008) Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 31:431–438PubMedCrossRef

11.

Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK (1997) Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 24:293–298PubMed

12.

Slauson DO, Hahn FF, Benjamin SA, Chiffelle TL, Jones RK (1976) Inflammatory sequences in acute pulmonary radiation injury. Am J Pathol 82:549–572PubMed

13.

Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS et al (1995) Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 33:919–924PubMedCrossRef

14.

Peerzada MM, Spiro TP, Daw HA (2010) Pulmonary toxicities of biologics: a review. Anticancer Drugs 21:131–139PubMedCrossRef

15.

Demedts M, Costabel U (2002) ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J 19:794–796PubMedCrossRef

16.

Hubbard R, Venn A, Smith C, Cooper M, Johnston I, Britton J (1998) Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case—control study. Am J Respir Crit Care Med 157:743–747PubMed

17.

Scott J, Johnston I, Britton J (1990) What causes cryptogenic fibrosing alveolitis? A case—control study of environmental exposure to dust. Br Med J 301:1015–1017CrossRef

18.

Hubbard R, Lewis S, Richards K, Johnston I, Britton J (1996) Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 347:284–289PubMedCrossRef

19.

Camus P, Kudoh S, Ebina M (2004) Interstitial lung disease associated with drug therapy. Br J Cancer 91:S18–S23PubMedCrossRef

20.

Merad M, Le Cesne A, Baldeyrou P, Mesurolle B, Le Chevalier T (1997) Docetaxel and interstitial pulmonary injury. Ann Oncol 8:191–194PubMedCrossRef

Titel: Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan
verfasst von: Moon Jin Kim
Gyeong-Won Lee
Jong Woo Seo
Hyun-Jung Kim
Sung-Nam Lim
Cheolwon Suh
Publikationsdatum: 01.10.2011
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 5/2011
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-010-9460-0

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan

Summary

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2011

Kit inhibitor APcK110 extends survival in an AML xenograft mouse model

5k, a novel β-O-demethyl-epipodophyllotoxin analogue, inhibits the proliferation of cancer cells in vitro and in vivo via the induction of G2 arrest and apoptosis

In vitro pharmacological study of monomeric platinum(III) hematoporphyrin IX complexes

A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials

Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide

The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie